Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00832494
Recruitment Status : Completed
First Posted : January 30, 2009
Last Update Posted : January 30, 2009
Information provided by:
Antisoma Research

January 29, 2009
January 30, 2009
January 30, 2009
September 2004
August 2007   (Final data collection date for primary outcome measure)
  • Safety and tolerability of combination
  • Tumor response rate
  • Time to tumor progression
  • Duration of response and stable disease; median and one-year survival
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
An Open Label, Randomized, Phase I/II Study of DMXAA in Combination With Carboplatin and Paclitaxel in Patients With Locally Advanced and Metastatic Non-Small Cell Lung Cancer
This study was designed to test the addition of DMXAA (now known as ASA404) to carboplatin and paclitaxel in patients with NSCLC.
The study was designed to determine the safety, tolerability and efficacy of DMXAA in combination with carboplatin and paclitaxel in patients with locally advanced and metastatic (Stage IIIb and IV) non-small cell lung cancer. The phase Ib part of the study evaluated dose levels of DMXAA at 600 mg/m2, 1200 mg/m2 and 1800 mg/m2. In the phase II part of the study, patients were randomized to receive carboplatin and paclitaxel alone or in combination with ASA404 1200 mg/m2. An additional single-arm study was undertaken to evaluate further patients at the 1800 mg/m2 dose level.
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Non-Small Cell Lung Cancer
Drug: DMXAA in combination with carboplatin and paclitaxel
Administered every 21 days
Other Name: DMXAA is now known as ASA404
Not Provided
McKeage MJ, Jameson MB; AS1404-201 Study Group Investigators. Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. J Thorac Dis. 2010 Dec;2(4):199-204. doi: 10.3978/j.issn.2072-1439.2010.02.04.1.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
August 2007
August 2007   (Final data collection date for primary outcome measure)


  1. Histologically confirmed non-small cell lung carcinoma designated as adenocarcinoma (including bronchoalveolar), squamous cell carcinoma or undifferentiated, mixed (adenocarcinoma and squamous) or large cell carcinoma.
  2. Locally advanced Stage IIIb disease, not curable with surgery or radiotherapy, or Stage IV disease.
  3. Aged ≥ 18 years of age.
  4. Karnofsky performance status of ≥ 70%.
  5. Life expectancy of ≥ 3 months.
  6. Hematological and biochemical indices at screening comprising:

    • An absolute neutrophil count of ≥ 2.0 x 109/L.
    • A platelet count of ≥ 100 x 109/L.
    • A hemoglobin level of ≥ 10 g/dL.
    • Adequate hepatic and renal function as defined by serum bilirubin ≤ 25 µmol/L; alkaline phosphatase, alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 times the upper limit of normal if no demonstrable liver metastasis or ≤ 5 times the upper limit of normal in the presence of liver metastasis; serum creatinine ≤ 120 µmol/L.
  7. At least one unidimensionally measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST).
  8. Providing written informed consent and be able to comply with study assessments and follow-up.


  1. Patients who had undergone major surgery, chemotherapy or radiation therapy (except palliative) within the previous 4 weeks.
  2. A known history of hypersensitivity to carboplatin, paclitaxel or any of their excipients.
  3. Previous exposure to DMXAA or other vascular targeting agents.
  4. Small cell lung cancer or mixed histology.
  5. Having received blood transfusions or growth factors to aid haematological recovery within 2 weeks of the scheduled baseline visit.
  6. Active serious infection within 2 weeks of screening.
  7. Clinically significant cardiac arrhythmias and known QTc prolongation.
  8. Evidence of severe or uncontrolled systemic disease that might interfere with study participation.
  9. A history of alcoholism, drug addiction or any psychiatric condition that would impair the patient's ability to comply with study procedures.
  10. Pregnant or lactating women and women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test.
  11. Patients should not have received within the two weeks prior to starting the study or be expected to need during the study period medications known to affect the QT interval or systemic serotonin levels.
  12. Concurrent or previous malignancy of a different tumor type within 5 years of starting the study, except for adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia.
  13. Clinical or radiological evidence of central nervous system metastases.
  14. Evidence of any other clinically significant disorder or laboratory finding that might compromise patient safety.
  15. Participation in any investigational drug study in which the study drug did not subsequently obtain a product license.
Sexes Eligible for Study: All
Child, Adult, Older Adult
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Gary Acton, Chief Medical Officer, Antisoma Research Limited
Antisoma Research
Not Provided
Principal Investigator: Mark McKeage Auckland Medical School, Auckland, New Zealand
Antisoma Research
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP